Equities research analysts forecast that Immunomedics, Inc. (NASDAQ:IMMU) will announce earnings per share (EPS) of ($0.32) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Immunomedics’ earnings. The lowest EPS estimate is ($0.32) and the highest is ($0.30). Immunomedics posted earnings of ($0.19) per share in the same quarter last year, which would suggest a negative year over year growth rate of 68.4%. The firm is expected to report its next earnings report on Thursday, February 14th.
According to Zacks, analysts expect that Immunomedics will report full-year earnings of ($1.20) per share for the current year, with EPS estimates ranging from ($1.33) to ($1.00). For the next financial year, analysts forecast that the firm will report earnings of ($0.88) per share, with EPS estimates ranging from ($1.32) to ($0.68). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that cover Immunomedics.
Immunomedics (NASDAQ:IMMU) last issued its earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.06). Immunomedics had a negative return on equity of 85.57% and a negative net margin of 12,701.21%. During the same quarter in the prior year, the business posted ($0.97) EPS.
Shares of NASDAQ:IMMU opened at $18.70 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 13.45 and a quick ratio of 13.45. The stock has a market cap of $3.55 billion, a price-to-earnings ratio of -18.16 and a beta of 1.93. Immunomedics has a twelve month low of $8.68 and a twelve month high of $27.33.
Several institutional investors have recently made changes to their positions in IMMU. Legal & General Group Plc lifted its holdings in shares of Immunomedics by 100.7% in the first quarter. Legal & General Group Plc now owns 52,358 shares of the biopharmaceutical company’s stock worth $765,000 after buying an additional 26,270 shares in the last quarter. Amalgamated Bank lifted its holdings in shares of Immunomedics by 47.4% in the second quarter. Amalgamated Bank now owns 19,954 shares of the biopharmaceutical company’s stock worth $472,000 after buying an additional 6,415 shares in the last quarter. Shaker Investments LLC OH raised its stake in Immunomedics by 218.2% in the second quarter. Shaker Investments LLC OH now owns 84,015 shares of the biopharmaceutical company’s stock valued at $1,989,000 after purchasing an additional 57,615 shares in the last quarter. Massachusetts Financial Services Co. MA raised its stake in Immunomedics by 1.4% in the second quarter. Massachusetts Financial Services Co. MA now owns 554,914 shares of the biopharmaceutical company’s stock valued at $13,135,000 after purchasing an additional 7,694 shares in the last quarter. Finally, TD Asset Management Inc. raised its stake in Immunomedics by 25.9% in the second quarter. TD Asset Management Inc. now owns 215,088 shares of the biopharmaceutical company’s stock valued at $5,091,000 after purchasing an additional 44,288 shares in the last quarter. 75.96% of the stock is currently owned by hedge funds and other institutional investors.
Immunomedics Company Profile
Immunomedics, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively.
Recommended Story: Capital gains and your 401(k) or IRA
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.